Publications
68
Citations
990
Est. group size
~2
Recurring co-author estimate
Active years
11
Publishing since 2015
Vidhya Karivedu's research focuses on clinical oncology, particularly the treatment of head and neck squamous cell carcinoma (a cancer affecting the mouth, throat, and related tissues) using combination drug therapies such as PARP inhibitors and immunotherapy agents. Related work examines how cancer patients, including those with melanoma, were affected by COVID-19, including outcomes disparities and interactions between immunosuppression and cancer immunotherapy. Overall, this is applied clinical cancer research involving clinical trials and outcomes studies rather than basic laboratory science.
Publication output has fluctuated over the past decade, rising to peaks in 2021, 2022, and 2025 with a notable dip in 2023-2024, suggesting an uneven but currently active publication pace.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Cancer Research Communications · 2025
- Supplementary Table S1 from Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025
- Supplementary Data Fig Info from Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025
- Supplementary Table S2 from Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025
- Fig S1 from Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025
- Table 1 from Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025
- Supplementary Table S4 from Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025
- Fig S4 from Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025
- Supplementary Table S3 from Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025
- Data from Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025
- Fig S3 from Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025
- Table 2 from Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025
- Fig S2 from Phase II Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025
- Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma
BMC Cancer · 2023
- Phase II study evaluating the efficacy of niraparib and dostarlimab (TSR-042) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) patients.
Journal of Clinical Oncology · 2023
- Journal of Clinical Oncology×16
- International Journal of Radiation Oncology*Biology*Physics×5
- Annals of Oncology×3
- JAMA Network Open×3
- JAMA Oncology×2
- Priyanka Bhateja
Medicine · The Ohio State University
- Lingbin Meng
Medicine · The Ohio State University
- Marcelo Bonomi
Medicine · The Ohio State University
- James W. Rocco
Medicine · The Ohio State University
- Darrion Mitchell
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile